Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0W5NP
|
|||
| Former ID |
DIB014324
|
|||
| Drug Name |
Anatumomab mafenatox
|
|||
| Synonyms |
ABR-214936; Fab5T4V13-SEAm9; PNU-214936; TTS-CD2; CD-2, Active Biotech
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Breast cancer [ICD-11: 2C60-2C65] | Terminated | [1] | |
| Company |
Pharmacia & Upjohn Inc
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Oncotrophoblast glycoprotein 5T4 (TPBG) | Target Info | . | [1] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | A phase II study of a 5T4 oncofoetal antigen tumour-targeted superantigen (ABR-214936) therapy in patients with advanced renal cell carcinoma. Br J Cancer. 2007 Feb 26;96(4):567-74. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.